QSPR Modeling of Biopharmaceutical Properties of Hydroxypropyl Methylcellulose (Cellulose Ethers) Tablets Based on Its Degree of Polymerization
- 5 Downloads
Quantitative structure-property relationship (QSPR) approach has been widely used in predicting physicochemical properties of compounds. However, its application in the estimation of formulation properties based on the polymer used in it to achieve desired formulation characteristics is an extremely challenging process. In the present research, predictive QSPR models were developed by correlating the physicochemical properties of varying grades of cellulose ethers (hydroxypropyl methylcellulose, HPMC) with those of nateglinide (NTG) containing tablets (in vitro and in vivo properties). Sustained release tablets of NTG were prepared by using different grades and concentrations of HPMC and subsequently characterized for in vitro as well as in vivo parameters. Further, QSPR models for individual formulation property were developed by correlating the polymeric physicochemical properties with the formulation characteristics. Subsequently, a true external validation method was used to validate the predictability of developed models. The dissolution study indicated Korsmeyer-Peppas as the best fit model following non-Fickian as drug transport mechanism extending the drug release up to 12 h. In vivo studies showed limited absorption of the NTG. Developed QSPR models showed promising validated predictability for formulation characteristics. The applicability of present work in formulation development could significantly reduce the time and cost expenditure on design trials without actually formulating a delivery system.
KEY WORDSQSPR modeling biopharmaceutical degree of polymerization HPMC in vivo
Absorption, Distribution, Metabolism, and Excretion
Area Under the Curve
Biopharmaceutical Classification System
Differential Scanning Calorimetry
Elimination Rate Constant
Fourier Transform Infrared
High Performance Liquid Chromatography
International Conference on Harmonization
Limit of Detection
Limit of Quantitation
Molecular Design Suite
Maximum Retention Time
Quantitative Structure-Property Relationship
Root Mean Square Error
Rotations Per Minute
United States Pharmacopeia
Volume of Distribution
van der Waals
The authors are grateful to Ashland Inc. Ltd., Netherlands for providing gift samples of different grades of HPMC (K4M, K15M, K35M, K100M, and K250 PH); Cipla Ltd. (Kurkumbh, Maharashtra, India) for kind gift sample of Nateglinide, Glenmark Pharmaceuticals (Mumbai, Maharashtra, India) for supplying gift sample of Gliclazide; and Colorcon Asia Ltd. (Goa, India) for providing gift samples of microcrystalline cellulose (Avicel PH102), magnesium stearate, and talc.
Compliance with Ethical Standards
Authors declare that the experiments are in compliance with the current laws of India.
Conflict of Interest
The authors declare that they have no conflict of interest.
Authors declare that the experiments comply with the current laws of India.
Statement of Human and Animal Rights
This article contained studies with animal subjects performed by the first author and was duly approved by the Institutional Animal Ethics Committee.
- 1.Mali RR, Goel V, Gupta S. Novel study in sustained release drug delivery system: a review. Int J Pharm Med Res. 2015;3:204–15.Google Scholar
- 2.Patel KB, Vyas JR, Upadhyay UM. Formulation and evaluation of sustained release matrix tablets of Nateglinide. J Drug Deliv Ther. 2015;5:19–25.Google Scholar
- 3.Dusane AR, Gaikwad PD, Bankar VH, Pawar SP. A review on: sustained released technology. Int J Res Ayurveda Pharm. 2011;2:1701–8.Google Scholar
- 4.Gupta MM, Brijesh R. A review on: sustained release technology. Int J Ther Appl [Internet]. 2012 [cited 2019 Mar 2];8:18–23. Available from: http://journal.npaa.in/admin/ufile/1372744692IJTA_8_18-23.pdf
- 5.Chugh I, Seth N, Rana AC, Gupta S. Oral sustained release drug delivery system: an overview. Int Res J Pharm. 2012;3:57–62.Google Scholar
- 11.Gaikwad VL, Bhatia MS, Singhvi I. Statistical modeling of physical characteristics of fast disintegrating glipizide tablets using polymeric properties. Int J Pharm Technol. 2013;5:5586–601.Google Scholar
- 13.Gaikwad VL, Bhatia MS, Singhvi I. Effect of polymeric properties on physical characteristics of fast disintegrating ibuprofen tablets: a statistical approach. Der Pharm Lett. 2013;5:140–7.Google Scholar
- 14.Fayet G, Rotureau P, Prana V, Adamo C. Prediction of physico-chemical properties for REACH based on QSPR models. In: De Rademaeker E, Fabiano B, Senni Buratti S, editors. Proc. 14th Int. Symp. Loss Prev. Saf. Promot. Process Ind. [Internet]. Florence; 2013 [cited 2019 Mar 2]. p. 925–30. Available from: https://hal-ineris.archives-ouvertes.fr/ineris-00976244
- 20.ICH. Stability testing: Photostability testing of new drug substances and products Q1B [Internet]. ICH. 1996 [cited 2019 Mar 2]. p. 1–12. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q1B/Step4/Q1B_Guideline.pdf.
- 21.TA Instruments. Interpreting unexpected events and transitions in DSC results [Internet]. 2016. Available from: http://www.tainstruments.com/pdf/literature/TA039.pdf. Accessed 01 Mar 2019.
- 22.TA Instruments. How to interpret the unexpected transitions in DSC results [Internet]. AZOM. 2015 [cited 2019 Mar 2]. p. 1–10. Available from: https://www.azom.com/article.aspx?ArticleID=12101.
- 23.Mettler Toledo. Interpreting DSC curves Part 1: Dynamic measurements [Internet]. Mettler Toledo. 2000 [cited 2019 Mar 2]. p. 1–28. Available from: http://www.masontechnology.ie/x/Usercom_11.pdf.
- 25.Raveendra Babu G, Rao AL, Sri Lakshmi SP, Kalapraveen T, Rao PS. Spectrophotometric methods for estimation of nateglinide in bulk drug and its dosage form. Int J Pharm Chem Biol Sci. 2013;3:1160–4.Google Scholar
- 26.USPNF. United States Pharmacopeia [USP] 22 – National Formulary [NF] 17. Rockville, MD: United States Pharmacopeial Convention, Inc.; 1995.Google Scholar
- 27.IPCommission. Indian Pharmacopeia. Ghaziabad: Indian Pharmacopoeia Commission, Govt. of India, Ministry of Health and Family Welfare; 1996.Google Scholar
- 28.ICH. Validation of analytical procedures: Text and methodology Q2(R1) [Internet]. ICH. 2005 [cited 2019 Mar 2]. p. 1–17. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf.
- 29.USPNF. United States Pharmacopeia [USP] 38 – National Formulary [NF] 33. Rockville, MD: United States Pharmacopeial Convention, Inc.; 2015.Google Scholar
- 30.FDA. Nateglinide Tablets [Internet]. U.S. Food Drug Adm. 2009 [cited 2019 Apr 1]. p. 1–2. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/077467s000lbl.pdf
- 31.Novartis Pharmaceuticals Canada Inc. PrStarlix* (Nateglinide): Product Monograph [Internet]. Novartis Pharm. Canada Inc. 2011 [cited 2019 Apr 1]. p. 1–34. Available from: https://www.novartis.ca/sites/www.novartis.ca/files/starlix_scrip_e.pdf.
- 32.DOW. Chemistry of METHOCEL™. Cellulose Ethers - a technical review [Internet]. Dow Chem. Co. 2013 [cited 2019 Apr 2]. p. 1–16. Available from: http://msdssearch.dow.com/PublishedLiteratureDOWCOM/dh_08e5/0901b803808e5f58.pdf?filepath=dowwolff/pdfs/noreg/198-02289.pdf&fromPage=GetDoc.
- 33.DOW. METHOCEL Cellulose Ethers. Technical Handbook [Internet]. Dow Chem. Co. 2002 [cited 2019 Apr 2]. p. 1–32. Available from: http://msdssearch.dow.com/PublishedLiteratureDOWCOM/dh_096d/0901b8038096d9ff.pdf?filepath=/pdfs/noreg/192-01062.pdf&fromPage=GetDoc.